Chagas disease (CD) affects 21 countries in the Americas and is caused by the parasite Trypanosomacruzi. A key molecule involved in CD is lysophosphatidylcholine (LPC), which has been studied in various contexts: in the saliva of insect vectors, during the establishment of infection in the vertebrate host, and for the parasite itself. This lipid can be produced by the action of phospholipases A2 (PLA2), enzymes that catalyze the hydrolysis of phospholipids releasing fatty acids and lysophospholipids, such as LPC. This study investigates LPC levels and PLA2 activities in the plasma of CD patients and compares these levels with those in healthy individuals and patients with idiopathic dilated cardiomyopathy (IDCM). Plasma from 64 CD patients, 54 healthy individuals, and 16 IDCM patients were analyzed. LPC levels and the activity of two types of phospholipase A2: secreted (sPLA2) and lipoprotein-associated (Lp-PLA2) were measured. LPC levels and sPLA2 activity were similar between CD patients and the control groups. However, there were notable differences in LPC levels and sPLA2 activity between subgroups of CD patients and IDCM patients. This study is the first to identify LPC in patients with CD across various stages of the disease. It also offers new insights into the biochemical changes observed in the plasma of patients with IDCM.
References
[1]
Organization, P.A.H.O. Chagas Disease 2024.
[2]
Nouvellet, P., Cucunubá, Z.M. and Gourbière, S. (2015) Ecology, Evolution and Control of Chagas Disease: A Century of Neglected Modelling and a Promising Future. AdvancesinParasitology, 87, 135-191. https://doi.org/10.1016/bs.apar.2014.12.004
[3]
Coura, J.R. and Dias, J.C.P. (2009) Epidemiology, Control and Surveillance of Chagas Disease: 100 Years after Its Discovery. MemóriasdoInstitutoOswaldoCruz, 104, 31-40. https://doi.org/10.1590/s0074-02762009000900006
[4]
Gourbière, S., Dorn, P., Tripet, F. and Dumonteil, E. (2011) Genetics and Evolution of Triatomines: From Phylogeny to Vector Control. Heredity, 108, 190-202. https://doi.org/10.1038/hdy.2011.71
[5]
Andrade, L.O. and Andrews, N.W. (2005) The Trypanosoma cruzi—Host-Cell Interplay: Location, Invasion, Retention. NatureReviewsMicrobiology, 3, 819-823. https://doi.org/10.1038/nrmicro1249
[6]
Echavarría, N.G., Echeverría, L.E., Stewart, M., Gallego, C. and Saldarriaga, C. (2021) Chagas Disease: Chronic Chagas Cardiomyopathy. Current Problems in Cardiology, 46, Article 100507. https://doi.org/10.1016/j.cpcardiol.2019.100507
[7]
Khan, S.A. and Ilies, M.A. (2023) The Phospholipase A2 Superfamily: Structure, Isozymes, Catalysis, Physiologic and Pathologic Roles. InternationalJournalofMolecularSciences, 24, Article 1353. https://doi.org/10.3390/ijms24021353
[8]
Golodne, D.M., Monteiro, R.Q., Graça-Souza, A.V., Silva-Neto, M.A.C. and Atella, G.C. (2003) Lysophosphatidylcholine Acts as an Anti-Hemostatic Molecule in the Saliva of the Blood-Sucking Bug Rhodnius Prolixus. JournalofBiologicalChemistry, 278, 27766-27771. https://doi.org/10.1074/jbc.m212421200
[9]
Lima, M.S., Carneiro, A.B., Souto-Padron, T., Jurberg, J., Silva-Neto, M.A.C. and Atella, G.C. (2018) Triatoma Infestans Relies on Salivary Lysophosphatidylcholine to Enhance Trypanosoma Cruzi Transmission. ActaTropica, 178, 68-72. https://doi.org/10.1016/j.actatropica.2017.10.022
[10]
Mesquita, R.D., Carneiro, A.B., Bafica, A., Gazos-Lopes, F., Takiya, C.M., Souto-Padron, T., etal. (2008) Trypanosoma cruzi Infection Is Enhanced by Vector Saliva through Immunosuppressant Mechanisms Mediated by Lysophosphatidylcholine. InfectionandImmunity, 76, 5543-5552. https://doi.org/10.1128/iai.00683-08
[11]
Gazos-Lopes, F., Oliveira, M.M., Hoelz, L.V.B., Vieira, D.P., Marques, A.F., Nakayasu, E.S., etal. (2014) Structural and Functional Analysis of a Platelet-Activating Lysophosphatidylcholine of Trypanosoma Cruzi. PLOS NeglectedTropicalDiseases, 8, e3077. https://doi.org/10.1371/journal.pntd.0003077
Xavier, S.S. (1999) Estudo longitudinal da morbi-mortalidade cardíaca da doença de Chagas em uma coorte de um grande centro urbano: Análise clínica eletrocardiográfica, radiológica e ecocardiográfica de 604 casos. Ph.D. Thesis, Universidade Federal do Rio de Janeiro.
[14]
Lowry, O., Rosebrough, N., Farr, A.L. and Randall, R. (1951) Protein Measurement with the Folin Phenol Reagent. JournalofBiologicalChemistry, 193, 265-275. https://doi.org/10.1016/s0021-9258(19)52451-6
[15]
Drzazga, A., Sowińska, A., & Koziołkiewicz, M. (2014) Lysophosphatidylcholine and Lysophosphatidylinosiol—Novel Promissing Signaling Molecules and Their Possible Therapeutic Activity. ActaPoloniae Pharmaceutica, 71, 887-899.
[16]
Law, S., Chan, M., Marathe, G.K., Parveen, F., Chen, C. and Ke, L. (2019) An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. InternationalJournalofMolecularSciences, 20, Article 1149. https://doi.org/10.3390/ijms20051149
[17]
Murakami, M. (2023) The Phospholipase A2 Superfamily as a Central Hub of Bioactive Lipids and Beyond. Pharmacology&Therapeutics, 244, Article 108382. https://doi.org/10.1016/j.pharmthera.2023.108382
[18]
Barber, M.N., Risis, S., Yang, C., Meikle, P.J., Staples, M., Febbraio, M.A., etal. (2012) Plasma Lysophosphatidylcholine Levels Are Reduced in Obesity and Type 2 Diabetes. PLOS ONE, 7, e41456. https://doi.org/10.1371/journal.pone.0041456
[19]
Taylor, L.A., Arends, J., Hodina, A.K., Unger, C. and Massing, U. (2007) Plasma Lyso-Phosphatidylcholine Concentration Is Decreased in Cancer Patients with Weight Loss and Activated Inflammatory Status. Lipids in Health and Disease, 6, Article No. 17. https://doi.org/10.1186/1476-511x-6-17
[20]
Harding, D., Chong, M.H.A., Lahoti, N., Bigogno, C.M., Prema, R., Mohiddin, S.A., etal. (2022) Dilated Cardiomyopathy and Chronic Cardiac Inflammation: Pathogenesis, Diagnosis and Therapy. JournalofInternalMedicine, 293, 23-47. https://doi.org/10.1111/joim.13556
[21]
Huang, F., Wang, K. and Shen, J. (2019) Lipoprotein‐Associated Phospholipase A2: The Story Continues. MedicinalResearchReviews, 40, 79-134. https://doi.org/10.1002/med.21597
[22]
Silva-Neto, M.A.C., Lopes, A.H. and Atella, G.C. (2016) Here, There, and Everywhere: The Ubiquitous Distribution of the Immunosignaling Molecule Lysophosphatidylcholine and Its Role on Chagas Disease. FrontiersinImmunology, 7, Article 62. https://doi.org/10.3389/fimmu.2016.00062
